-
61.发明授权公开(公告)号：US10919894B2
公开(公告)日：2021-02-16
申请号：US16745569
申请日：2020-01-17
Applicant: GlaxoSmithKline Biologicals SA
Inventor： Helene G. Bazin-Lee , Yufeng Li
IPC: A61K31/522 , C07D473/18 , A61K31/52 , A61K39/39 , A61K39/00
Abstract: Compounds of formula (I): wherein: R1 is butoxy or methylbutoxy; R2 is a group having the structure: where n is an integer having a value of five; Het is a six-membered saturated heterocycle containing five carbon atoms and one nitrogen atom, wherein Het is attached to the —(CH2)n— moiety at the carbon 4 position of the heterocycle; and R3 is hydrogen; or pharmaceutically acceptable salts thereof; and their use as vaccine adjuvants and in the treatment of various disorders.
-
公开(公告)号：US20210024553A1
公开(公告)日：2021-01-28
申请号：US16989235
申请日：2020-08-10
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Helene G. BAZIN-LEE , Laura S. BESS , David A. JOHNSON
IPC: C07F9/6558 , C07F9/10 , C07F9/6561
Abstract: The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)-active and toll-like receptor (TLR8)-active imidazoquinolines and oxoadenines.
-
公开(公告)号：US10745449B2
公开(公告)日：2020-08-18
申请号：US16023164
申请日：2018-06-29
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Normand Blais , Cindy Castado , Patrick Chomez , Marianne Dewerchin
IPC: A61K39/00 , A61K39/02 , A61K47/00 , C07K14/21 , A61K39/102 , A61K39/104 , C07K16/12
Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
-
公开(公告)号：US20200222526A1
公开(公告)日：2020-07-16
申请号：US16630951
申请日：2018-07-16
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Kathryn HASHEY , Padma MALYALA , Marcelo SAMSA , Olga SLACK , Dong YU , Alan STOKES , Rashmi JALAH
IPC: A61K39/205 , A61K9/127
Abstract: Nucleic acid based vaccine constructs encoding Lyssaviral antigens are useful in preventing and treating diseases. Self-amplifying RNA molecules encoding Lyssaviral antigens provide potent and long-lasting immunity.
-
公开(公告)号：US20200164061A1
公开(公告)日：2020-05-28
申请号：US16782268
申请日：2020-02-05
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Stefano COLLOCA , Riccardo CORTESE , Antonella FOLGORI , Alfredo NICOSIA
Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.
-
Patent Agency Ranking
公开(公告)号：US10603369B2
公开(公告)日：2020-03-31
申请号：US15887203
申请日：2018-02-02
Applicant: GlaxoSmithKline Biologicals SA
Inventor： Barbara Baudner , David Skibinski , Manmohan Singh , Derek O'Hagan
IPC: A61K39/00 , A61K31/4375 , A61K31/66 , A61K33/06 , A61K39/39 , A61K39/12 , A61K39/102 , A61K39/116 , A61K39/295
Abstract: Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. compositions which are adjuvanted with an oil-in-water emulsion adjuvant.
-
公开(公告)号：US10584355B2
公开(公告)日：2020-03-10
申请号：US15339225
申请日：2016-10-31
Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES , GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Nancy J. Sullivan , Gary J Nabel , Clement Asiedu , Cheng Cheng , Alfredo Nicosia , Riccardo Cortese , Virginia Ammendola , Stefano Colloca
IPC: C12N15/86 , A61K39/12 , C07K14/005 , C12N7/00 , A61K39/00
Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
-
公开(公告)号：US20200000912A1
公开(公告)日：2020-01-02
申请号：US16471583
申请日：2017-12-19
Applicant: GlaxoSmithKline Biologicals SA
Inventor： Margherita COCCIA , Arnauld Michel DIDIERLAURENT
IPC: A61K39/39
Abstract: The present invention relates to methods for inducing an immune response, in particular methods for adjuvanting the immune response to an antigen comprising the separate administration of a saponin and a TLR4 agonist.
-
公开(公告)号：US20190315812A1
公开(公告)日：2019-10-17
申请号：US16458365
申请日：2019-07-01
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Matthew BOTTOMLEY , Enrico MALITO , Manuele MARTINELLI
IPC: C07K14/22 , A61K39/095
Abstract: Modified meningococcal fHbp polypeptides with increased stability.
-
公开(公告)号：US20190298854A1
公开(公告)日：2019-10-03
申请号：US16082674
申请日：2017-03-06
Inventor： Abdelatif A ELOUAHABI , Patrick POHLHAUS , Laurent Bernard Jean STRODIOT , Ashley GALLOWAY , Jin Christiane Lee , Michele R. STONE
Abstract: The present invention concerns drug delivery particles which can prevent interaction between a biologically-active cargo comprised within the particles and components of an aqueous environment in which said particles are present. The particles are sensitive to pH such that above a threshold pH level the biologically-active cargo becomes accessible to the surrounding environment. Such particles are accordingly useful for stably storing a biologically-active cargo in an aqueous composition containing components which would otherwise interact deleteriously with the cargo, and releasing the cargo to mediate a biological effect in the body of an animal, such as a human, to which the composition is administered. Also provided are compositions comprising such particles, as well as methods for making and using such particles and compositions.
-
-
-
-
-
-
-
-
-
Search Results
600
records
(took 0.027 seconds)
